GET DAILY SIGNALSSeaStar Medical Holding (ICU) Analyst Targets Signal +426% Upside Potential
Key Takeaways
- The central $10 target is the arithmetic mean of two verified analyst price targets, $8 and $12, giving a wide, low-to-high range that signals unusually high uncertainty.
- With shares recently trading near $1.90, reaching $10 would require roughly 426% upside, a very large move by any standard.
- The higher, $12 target is more than six times the recent price, while the lower, $8 target still implies a roughly 320% gain.
- The strongest supporting factors are early commercial traction for its Selective Cytopheretic Device (SCD), revenue beats, and a Maxim Group target raise in May 2026.
- The biggest risks are a micro-cap balance sheet, recurring net losses, a history of reverse splits, and very thin analyst coverage (just two tracked targets).
- For more context, explore Major News, Today's Price Move, a detailed Forecast, and Earnings coverage for ICU.
- You can also monitor evolving market conditions with Trending AI Robots for signal-based ideas.
Understanding the Analyst Price Targets
SeaStar Medical Holding Corporation (ICU) is a commercial-stage medical device company developing the Selective Cytopheretic Device (SCD), a cell-directed extracorporeal therapy aimed at reducing the consequences of hyperinflammation on vital organs. It is a stock, not an ETF.
Coverage is thin. Independent aggregator data from S&P Global points to two tracked 12-month price targets: $8 on the low end and $12 on the high end, for a calculated mean of $10. Maxim Group analyst Anthony Vendetti maintains a Buy rating and raised his target to $8 from $6 on May 14, 2026, citing better-than-expected first-quarter revenue, gross margin, and loss per share, while lifting the firm's 2026 and 2027 revenue estimates. A second, higher $12 objective rounds out the range. Because only two targets exist, the $10 mean should be read as a rough benchmark, not a robust, widely followed consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently traded near $1.90, down sharply over the trailing year. Reaching $10 would require an increase of about 426%, which qualifies as a very large move. SeaStar's pediatric device has received Humanitarian Device Exemption (HDE) approval for acute kidney injury, and the company is working toward broader adult indications. Yet the path to $10 is fundamentally different from a routine re-rating: it would require a multiple-fold expansion in the stock price on a market capitalization of roughly $10 million, sustained revenue growth from a very small base, and meaningfully narrower losses.
Factors That Could Support a Move Toward the Target
- Early commercial momentum for the SCD platform and progress toward additional indications, including adult acute kidney injury.
- Revenue beats: third-quarter 2026 revenue of about $640,000 topped consensus near $450,500, and first-quarter results also exceeded estimates on revenue and gross margin.
- Positive analyst revisions, including the Maxim Group target increase to $8 from $6.
- Any FDA or regulatory milestones, expanded reimbursement, or new clinical data that broaden the addressable patient population.
Risks That Could Prevent the Target From Being Reached
- Persistent net losses and a heavily negative operating profile; third-quarter 2026 EPS of about -$1.03 missed the roughly -$0.93 estimate.
- A thin balance sheet and a history of reverse stock splits, which heightens dilution and capital-raising risk for a micro-cap.
- Extremely limited analyst coverage, leaving the price target range wide and the underlying assumptions thinly scrutinized.
- Competition in acute kidney injury and critical-care medical devices, plus slow hospital adoption and reimbursement uncertainty.
- Macro and sector rotation away from speculative, early-stage healthcare names.
Technical Levels and Market Structure
ICU trades near its recent and 52-week lows, in the low single digits after a prolonged decline. Long-term chart structure is distorted by multiple reverse splits, which makes durable support and resistance levels unreliable for this name. The $8 and $12 price targets sit far above the current trading range and should be treated as valuation benchmarks rather than nearby technical milestones. Investors should watch whether the stock can hold above the roughly $1.84-to-$1.90 zone that has marked its recent floor. From what I see, monitoring these levels closely helps frame realistic expectations.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, and the two tracked targets here fall within that convention. Because coverage is so limited, the actual assumptions behind each target vary materially. Key items to monitor include quarterly revenue and loss-per-share trends, any guidance or analyst target revisions, regulatory and clinical updates for the SCD platform, financing and dilution announcements, and broader risk appetite for speculative healthcare stocks. I’m watching this closely as new data emerges.
Using AI Daily Buy/Sell Signals for Dynamic Insights
For traders seeking a more dynamic view, AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning. Because signals update as conditions evolve, they can complement fundamental research on names like ICU.
Final Assessment
The $10 central target is the mean of two widely separated analyst objectives, $8 and $12, and implies a very large move of roughly 426% from a recent price near $1.90. Support rests on early SCD commercialization, revenue beats, and a recent target increase from Maxim Group, while the principal obstacles are recurring losses, a thin balance sheet, a reverse-split history, and extremely limited coverage. The wide target range reflects genuine disagreement and uncertainty rather than a firm directional signal. Whether ICU approaches $10 will depend on sustained revenue growth, narrower losses, and new regulatory or commercial milestones, none of which is assured. Investors should monitor upcoming earnings, analyst revisions, and any financing developments before drawing conclusions.
Exploring Tickeron AI Tools for Research
In my own analysis of names like ICU, I find Tickeron’s AI tools helpful for cross-checking fundamentals against broader market patterns. The AI Daily Buy/Sell Signals platform stands out because it processes real-time data across thousands of securities, offering a practical way to stay informed without constant manual effort. It has become a regular part of how I review potential opportunities and track shifts in sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ICU in downward trend: 10-day moving average broke below 50-day moving average on October 21, 2026
The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 80 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 34 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ICU entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ICU's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 150 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ICU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.929) is normal, around the industry mean (3.498). P/E Ratio (-0.995) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement